ArticleAmerican journal of cancer research2016
Upregulating miR-146a by physcion reverses multidrug resistance in human chronic myelogenous leukemia K562/ADM cells.
Article in American journal of cancer research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 18 citations in OpenAlex.
- MicroRNA‑145 promotes the apoptosis of leukemic stem cells and enhances drug‑resistant K562/ADM cell sensitivity to adriamycin via the regulation of ABCE1.International journal of molecular medicine · 2020Article
- Emodin reverses 5-Fu resistance in human colorectal cancer via downregulation of PI3K/Akt signaling pathway.American journal of translational research · 2020Article
- Assembly and Annotation of a Draft Genome of the Medicinal PlantFrontiers in plant science · 2019Article
Corrections and comments
- Retraction · 2020-08-01Duplication of/in Article · Investigation by Third Party · Paper Mill · · see also: https://scienceintegritydigest.com/2020/02/21/the-tadpole-paper-mill/
- Retracted
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to evaluate the role of miR-146a in the drug resistance of chronic myelogenous leukemia (CML) cells (K562/ADM) and to investigate the reversal effect of physcion, a natural compound, on the multidrug-resistance in CML. Our results showed that miR-146a was significantly downregulated in drug-resistant K562 cells and the overexpression of miR-146a in K562/ADM cells could restore the sensitivity to adriamycin (ADM). In addition, our results showed that the downregulation of miR-146a was associated with increase in CXCR4 expression, which was a direct target of miR-146a. Moreover, our findings also provided experimental evidence that physcion could enhance the anti-proliferative effect of ADM in K562/ADM cells by upregulating miR-146a. In conclusion, this present study showed that miR-146a conferred ADM resistance in CML cells and physcion could improve the sensitivity of K562/ADM cells by enhancing apoptosis via upregulating miR-146a.
Indexed as
Identifiers
27904770PMC5126272W2560585201What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.